Monovalent inactivated influenza vaccine

BIOLOGICAL2 trials

Sponsors

Novartis Vaccines

Conditions

Pre-pandemic Influenza VaccinePrepandemic Influenza Vaccine

Phase 2

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects

CompletedNCT00841646

Novartis VaccinesPrepandemic Influenza Vaccine

Start: 2008-12-31End: 2009-11-30Updated: 2016-12-01

Phase 3

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

CompletedNCT00848029

Novartis VaccinesPre-pandemic Influenza Vaccine

Start: 2008-11-30End: 2009-06-30Updated: 2016-12-01